- Tigem Research Highlights
-
MiT/TFE factors control ER ‐phagy via transcriptional regulation of FAM 134B
-
De novo SMARCA2 variants clustered outside the helicase domain cause a new recognizable syndrome with intellectual disability and blepharophimosis distinct from Nicolaides-Baraitser syndrome
-
A substrate-specific mTORC1 pathway underlies Birt–Hogg–Dubé syndrome
-
Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin.
- Our Vision
-
TIGEM (Telethon Institute of Genetics and Medicine) is an international research institute dedicated to the discovery of the mechanisms underlying rare genetic diseases and the development of innovative therapies. Learn more >>
- Institutional Partnership
-
Tigem can count on an Institutional Partnership with the Department of Translational Medicine of the Federico II University of Naples
- Upcoming Seminars and Events
-
NOTICE:
Due to the pandemic caused by Covid19, all TIGEM seminars have been postponed.TIGEM will stay open but the activities have been reduced: according to ISS guidelines (https://www.iss.it/coronavirus), we implemented very strict procedures in order to guarantee the safety of all personnel.
